JP2019524889A5 - - Google Patents

Download PDF

Info

Publication number
JP2019524889A5
JP2019524889A5 JP2019530368A JP2019530368A JP2019524889A5 JP 2019524889 A5 JP2019524889 A5 JP 2019524889A5 JP 2019530368 A JP2019530368 A JP 2019530368A JP 2019530368 A JP2019530368 A JP 2019530368A JP 2019524889 A5 JP2019524889 A5 JP 2019524889A5
Authority
JP
Japan
Prior art keywords
pharmaceutical composition
subject
composition according
effective amount
therapeutically effective
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019530368A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019524889A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/047584 external-priority patent/WO2018035449A1/en
Publication of JP2019524889A publication Critical patent/JP2019524889A/ja
Publication of JP2019524889A5 publication Critical patent/JP2019524889A5/ja
Priority to JP2022090843A priority Critical patent/JP2022116294A/ja
Pending legal-status Critical Current

Links

JP2019530368A 2016-08-18 2017-08-18 骨疾患の治療のためのPPARγアゴニスト Pending JP2019524889A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2022090843A JP2022116294A (ja) 2016-08-18 2022-06-03 骨疾患の治療のためのPPARγアゴニスト

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662376732P 2016-08-18 2016-08-18
US62/376,732 2016-08-18
PCT/US2017/047584 WO2018035449A1 (en) 2016-08-18 2017-08-18 Pparϒ agonist for treatment of bone disorders

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022090843A Division JP2022116294A (ja) 2016-08-18 2022-06-03 骨疾患の治療のためのPPARγアゴニスト

Publications (2)

Publication Number Publication Date
JP2019524889A JP2019524889A (ja) 2019-09-05
JP2019524889A5 true JP2019524889A5 (enExample) 2020-10-01

Family

ID=61197122

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2019530368A Pending JP2019524889A (ja) 2016-08-18 2017-08-18 骨疾患の治療のためのPPARγアゴニスト
JP2022090843A Withdrawn JP2022116294A (ja) 2016-08-18 2022-06-03 骨疾患の治療のためのPPARγアゴニスト

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2022090843A Withdrawn JP2022116294A (ja) 2016-08-18 2022-06-03 骨疾患の治療のためのPPARγアゴニスト

Country Status (11)

Country Link
US (1) US20190167660A1 (enExample)
EP (1) EP3500269A4 (enExample)
JP (2) JP2019524889A (enExample)
KR (1) KR20190065252A (enExample)
CN (1) CN109843292A (enExample)
AU (1) AU2017313842A1 (enExample)
BR (1) BR112019003133A2 (enExample)
CA (1) CA3033971A1 (enExample)
EA (1) EA201990513A1 (enExample)
SG (2) SG10202101500WA (enExample)
WO (1) WO2018035449A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HK1249847A1 (zh) 2015-03-09 2018-11-16 Intekrin Therapeutics, Inc. 用於治疗非酒精性脂肪肝疾病和/或脂肪营养不良的方法
KR20200036808A (ko) 2017-04-03 2020-04-07 코히러스 바이오사이언시스, 인크. 진행성 핵상 마비 치료를 위한 PPARγ 작용제

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA02010651A (es) * 2000-04-28 2003-03-10 Sankyo Co Moduladores de receptor activado de proliferador de peroxisoma-gamma.
US7223761B2 (en) * 2003-10-03 2007-05-29 Amgen Inc. Salts and polymorphs of a potent antidiabetic compound
US20050250820A1 (en) * 2004-03-08 2005-11-10 Amgen Inc. Therapeutic modulation of PPARgamma activity
SG11201505944QA (en) * 2013-01-30 2015-08-28 Intekrin Therapeutics Inc PPARγ AGONISTS FOR TREATMENT OF MULTIPLE SCLEROSIS
TWI699200B (zh) * 2014-10-10 2020-07-21 英商邊緣生物科技有限公司 用於預防及治療骨質疏鬆症之經取代之芳族化合物及醫藥組合物

Similar Documents

Publication Publication Date Title
US20240299381A1 (en) Methods of administering elagolix
RU2018110647A (ru) Арильные, гетероарильные и гетероциклические соединения для лечения заболеваний
MX2011007854A (es) Metodos para tratar infartos agudos al miocardio y trastornos relacionados.
Jabbour et al. Bisphosphonates inhibit bone remodeling in the jaw bones of rats and delay healing following tooth extractions
PH12015502691A1 (en) Use of high dose pridopidine for treating huntington's disease
JP2015517493A5 (enExample)
BR112014015482A2 (pt) compostos carbamato de fenila para uso no alívio ou tratamento de dor e dor neuropática
JP2015505564A5 (enExample)
RU2016114098A (ru) Новое производное аналога инсулина
EA202193190A1 (ru) Композиция, включающая придопидин и его аналог, для лечения болезни гентингтона и ее симптомов
ZA202000028B (en) Use of vibegron to treat overactive bladder
MX2021009539A (es) Derivado del profarmaco 6-oxo-1,6-dihidropiridazina, metodo de preparacion del mismo y aplicacion del mismo en medicina.
JP2019507786A5 (enExample)
JP2016505050A5 (enExample)
RU2020120156A (ru) Лечение приливов и потери костной ткани, вызванных андрогенной депривационной терапией с применением цис-кломифена
JP2018536638A5 (enExample)
JP2023549849A5 (enExample)
JP2019529569A5 (enExample)
HRP20211661T1 (hr) Igmezin, namijenjen upotrebi u liječenju alzheimerove bolesti
JP2022116294A (ja) 骨疾患の治療のためのPPARγアゴニスト
JP2020505448A5 (enExample)
RU2013126798A (ru) Комбинированная терапия дексаметазоном
RU2015152175A (ru) Комбинация ro5503781, капецитабина и оксалиплатина для терапии рака
EA201992690A1 (ru) Применение вибегрона для лечения гиперактивного мочевого пузыря
ZA202201789B (en) Solid oral dosage form comprising naproxen and vitamin b6